Keywords: Actelion, Epoprostenol "ACT", Japan, Approval, PAH, Pulmonary arterial hypertension, Veletri

Japanese approval for Actelion's epoprostenol "ACT"

Article | 19 February 2013

Print This

Europe’s largest biotech firm Actelion (SIX: ATLN) yesterday announced that Japan's Ministry of Health, Labor and Welfare had ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in